This SuperSeries is composed of the SubSeries listed below.
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Specimen part, Disease, Disease stage